Overcoming Barriers to Autologous Stem Cell Transplantation in Multiple Myeloma: Recommendations from a Multidisciplinary Roundtable Discussion

Autologous stem cell transplantation (ASCT) is a standard of care treatment for patients with multiple myeloma (MM). However, only 20% to 30% of patients with MM for whom the procedure is indicated undergo ASCT. Barriers to ASCT may be informational, financial, logistic, or cultural and may affect patients and treating oncologists. Available and accessible accurate ASCT-related information is essential to overcome these barriers. Such resources can be created by blood and marrow transplantation societies and patient advocacy groups, ideally in collaboration with MM specialists at transplant centers. An umbrella office at the society level is also recommended to connect oncologists, advocacy groups, and transplantation specialists; provide informational resources to patients; and conduct research into region- and population-specific barriers to ASCT.(c) 2023 Published by Elsevier Inc. on behalf of The American Society for Transplantation and Cellular Therapy.

Automated summary

Autologous stem cell transplantation is a standard treatment for multiple myeloma patients, but only a small percentage of eligible patients undergo this procedure. Overcoming barriers to transplantation requires the availability of accurate information and resources, which can be created through collaboration between transplantation societies, patient advocacy groups, and specialists.